Tay-Sachs Disease – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of Tay-Sachs disease comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the diagnosed prevalence of Tay-Sachs disease for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the countries covered in this report.
Clarivate Epidemiology’s Tay-Sachs disease forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of Tay-Sachs disease over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology provides at least 20 years of forecast data for the following Tay-Sachs disease patient populations:
- Diagnosed prevalence of Tay-Sachs disease.
Aishwarya S. Ambat, M.P.H., Epidemiologist , Epidemiology. She received her M.P.H. from the Manipal Academy of Higher Education in India and holds a bachelor’s degree in physiotherapy. Her areas of interest are rheumatic disease and cancer epidemiology.
Alexandre Vo Dupuy, M.Sc., Pharm.D., is a principal epidemiologist at Clarivate. Previously, he worked in the fields of consulting and real-world evidence and at a major pharmaceutical company. He obtained his doctor of pharmacy from Descartes University in Paris and his master’s degree in pharmacoepidemiology from the University of Bordeaux. He has worked in multiple therapy areas, with a focus on cancer epidemiology. He also codeveloped a scenario-based forecast for COVID-19.